Median Technologies’ eyonis (LCS) software, which recently gained FDA clearance, will be integrated into Tempus AI’s cardiac ...

Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine, today announced a collaboration with Median Technologies (EPA: ALMDT) to bring Median’s ...

Tempus AI, Inc. (NASDAQ:TEM) is one of the best Nancy Pelosi Stocks to buy in 2026. On January 27, Tempus AI, Inc. (NASDAQ:TEM) confirmed that its Immune Profile Score Test accurately predicts patient ...

Regulatory News: Median Technologies (FR0011049824, ALMDT, "Median" or the "Company"), developer of eyonis®, a suite of ...

Tempus AI recently reported clinical validation results showing its Immune Profile Score (IPS) more accurately predicts outcomes for patients on immune checkpoint inhibitors than conventional ...

Tempus Next supports providers in closing gaps in care for eligible patients based on clinical guidelines. “Staying current with rapidly evolving clinical guidelines—especially regarding biomarker ...

Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, will participate in TD Cowen's/Securities' 4th Annual Tools/Dx Revolution ...

RNA sequencing provides a comprehensive view of biological information, offering deeper insights into disease mechanisms, including improved fusion detection. As a powerful tool in research and ...